Niccola Funel

List of Publications by Year
in descending order

89 papers	4,763 citations	109137 35 h-index	98622 67 g-index
91 all docs	91 docs citations	91 times ranked	7968 citing authors

#	Article	IF	Citations
1	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. Cancers, 2021, 13, 4131.	1.7	8
2	Silver Nanoparticle-Coated Polyhydroxyalkanoate Based Electrospun Fibers for Wound Dressing Applications. Materials, 2021, 14, 4907.	1.3	11
3	Prognostic impact of conservative surgery for pancreatic IPMNs. Surgical Oncology, 2021, 38, 101582.	0.8	7
4	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2342-2345.	1.1	4
5	Detailing the ultrastructureâ€™s increase of prion protein in pancreatic adenocarcinoma. World Journal of Gastroenterology, 2021, 27, 7324-7339.	1.4	2
6	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2020, 271, 1137-1147.	2.1	47
7	The dichotomous role of the glycolytic metabolism pathway in cancer metastasis: Interplay with the complex tumor microenvironment and novel therapeutic strategies. Seminars in Cancer Biology, 2020, 60, 238-248.	4.3	65
8	The occurrence of prion protein in surgically resected pancreatic adenocarcinoma. Pancreatology, 2020, 20, 1218-1225.	0.5	6
9	Pancreatic serous cystoadenoma (CSA) showing increased tracer uptake at 68-GaDOTA-peptide Positron Emission Tomography (68Ga-DOTA-peptide PET-CT): a case report. BMC Surgery, 2020, 20, 331.	0.6	9
10	Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds. British Journal of Cancer, 2020, 123, 644-656.	2.9	29
11	Triticum vulgare Extract Modulates Protein-Kinase B and Matrix Metalloproteinases 9 Protein Expression in BV-2 Cells: Bioactivity on Inflammatory Pathway Associated with Molecular Mechanism Wound Healing. Mediators of Inflammation, 2020, 2020, 1-13.	1.4	9
12	A Model of a Zebrafish Avatar for Co-Clinical Trials. Cancers, 2020, 12, 677.	1.7	36
13	3-(6-Phenylimidazo [2,1-b][1,3,4]thiadiazol-2-yl)-1H-Indole Derivatives as New Anticancer Agents in the Treatment of Pancreatic Ductal Adenocarcinoma. Molecules, 2020, 25, 329.	1.7	39
14	Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells. European Journal of Medicinal Chemistry, 2020, 189, 112088.	2.6	49
15	Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. JCI Insight, 2020, 5, .	2.3	36
16	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. World Journal of Gastroenterology, 2020, 26, 2792-2809.	1.4	23
17	Robotic-assisted versus open left pancreatectomy for cystic tumours: A single-centre experience. Journal of Minimal Access Surgery, 2020, 16, 66.	0.4	4
18	A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 234-242.	1.3	36

#	Article	IF	Citations
19	Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. Anticancer Research, 2019, 39, 3609-3614.	0.5	8
20	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. Cancers, 2019, 11, 1181.	1.7	16
21	Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984123.	1.4	35
22	Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers, 2019, 11, 638.	1.7	57
23	Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Biochemical Pharmacology, 2019, 166, 128-138.	2.0	12
24	New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism. Expert Review of Clinical Pharmacology, 2019, 12, 1081-1090.	1.3	22
25	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma. EBioMedicine, 2019, 39, 215-225.	2.7	41
26	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. International Journal of Cancer, 2019, 144, 1275-1283.	2.3	36
27	The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. Pharmacogenomics, 2019, 20, 49-68.	0.6	23
28	Myoclonus epilepsy, retinitis pigmentosa, leukoencephalopathy and cerebral calcifications associated with a novel m.5513G>A mutation in the MT-TW gene. Biochemical and Biophysical Research Communications, 2018, 500, 158-162.	1.0	5
29	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	5.8	188
30	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Carcinogenesis, 2018, 39, 360-367.	1.3	16
31	Pancreatoduodenectomy without Vascular Resection in Patients with Primary Resectable Adenocarcinoma and Unilateral Venous Contact: A Matched Case Study. Gastroenterology Research and Practice, 2018, 2018, 1-8.	0.7	2
32	Liquid biopsies to optimize therapeutic efficacy in unresponsive lung cancer patients. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 761-763.	1.5	1
33	TGF-Î² induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nature Communications, 2018, 9, 1845.	5.8	101
34	Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells. PLoS ONE, 2018, 13, e0197493.	1.1	14
35	5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. Oncotarget, 2018, 9, 16437-16450.	0.8	12
36	Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. Journal of Hematology and Oncology, 2017, 10, 9.	6.9	65

#	Article	IF	Citations
37	SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Scientific Reports, 2017, 7, 43812.	1.6	15
38	Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Scientific Reports, 2017, 7, 44686.	1.6	66
39	Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors. Scientific Reports, 2016, 6, 39565.	1.6	15
40	Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis, 2016, 37, 957-964.	1.3	14
41	Robotic pancreatoduodenectomy with vascular resection. Langenbeck's Archives of Surgery, 2016, 401, 1111-1122.	0.8	52
42	The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacyâ€"Letter. Clinical Cancer Research, 2016, 22, 2594-2594.	3.2	0
43	Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget, 2016, 7, 28556-28569.	0.8	19
44	FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 6987.	1.4	68
45	MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinomaâ€"a step towards personalized therapy. Clinical Epigenetics, 2015, 7, 129.	1.8	22
46	<scp>TERT</scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	2.3	57
47	Pancreatic Cancer. Gastroenterology Research and Practice, 2015, 2015, 1-2.	0.7	2
48	Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. European Radiology, 2015, 25, 751-759.	2.3	51
49	microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. European Journal of Cancer, 2015, 51, 1389-1404.	1.3	94
50	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	9.4	224
51	Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression. Lancet, The, 2015, 385, S37.	6.3	54
52	The role of miR-21 and miR-211 on MMP9 regulation in pancreatic ductal adenocarcinoma: cooperation in invasiveness behaviors?. Epigenomics, 2015, 7, 333-335.	1.0	8
53	AKT1 and SELP Polymorphisms Predict the Risk of Developing Cachexia in Pancreatic Cancer Patients. PLoS ONE, 2014, 9, e108057.	1.1	34
54	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter, 2014, 4, e955386.	2.6	42

#	Article	IF	Citations
55	A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Pharmacogenomics, 2014, 15, 609-618.	0.6	10
56	Expression of SP7, RUNX1, DLX5, and CTNNB1 in Human Mesenchymal Stem Cells Cultured on Xenogeneic Bone Substitute as Compared With Machined Titanium. Implant Dentistry, 2014, Publish Ahead of Print, 407-15.	1.7	4
57	Advances in Primary Cell Culture of Pancreatic Cancer. , 2014, , 11-38.		0
58	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Digestive and Liver Disease, 2014, 46, 479-493.	0.4	108
59	MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression. Gastroenterology, 2014, 146, 268-277.e18.	0.6	141
60	Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice. European Journal of Pharmacology, 2014, 729, 37-44.	1.7	8
61	Role of CYB5A in Pancreatic Cancer Prognosis and Autophagy Modulation. Journal of the National Cancer Institute, 2014, 106, djt346.	3.0	65
62	miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells. Nucleosides, Nucleotides and Nucleic Acids, 2014, 33, 384-393.	0.4	58
63	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	9.4	294
64	Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/Î²-catenin signalling in pancreatic adenocarcinoma. Oncotarget, 2014, 5, 5335-5349.	0.8	50
65	Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells. Current Drug Targets, 2014, 15, 1331-1340.	1.0	19
66	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 2013, 45, 95-99.	0.4	45
67	Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer. Current Pharmaceutical Design, 2013, 19, 940-950.	0.9	61
68	Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Metâ€“driven Pancreatic Carcinoma. Cancer Research, 2013, 73, 6745-6756.	0.4	79
69	Vascular Dysfunction in a Mouse Model of Rett Syndrome and Effects of Curcumin Treatment. PLoS ONE, 2013, 8, e64863.	1.1	41
70	Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Current Pharmaceutical Design, 2013, 19, 940-50.	0.9	22
71	Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1735-1746.	1.9	84
72	Dextran-Catechin Conjugate: A Potential Treatment Against the Pancreatic Ductal Adenocarcinoma. Pharmaceutical Research, 2012, 29, 2601-2614.	1.7	78

#	Article	IF	Citations
73	The odd case of a small and mucinous-like acinar cell cystoadenocarcinoma of the pancreas. Pancreatology, 2012, 12, 421-422.	0.5	4
74	Loss of 18q22.3 Involving the Carboxypeptidase of Glutamate-like Gene Is Associated with Poor Prognosis in Resected Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 524-533.	3.2	21
75	High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer. PLoS ONE, 2012, 7, e49145.	1.1	67
76	Magnetic carbon nanotubes: a new tool for shepherding mesenchymal stem cells by magnetic fields. Nanomedicine, 2011, 6, 43-54.	1.7	32
77	Loss of Heterozygosity Status of D9S105 Marker Is Associated with Downregulation of KrÃ¼ppel-Like Factor 4 Expression in Pancreatic Ductal Adenocarcinoma and Pancreatic Intraepithelial Lesions. Pancreatology, 2011, 11, 30-42.	0.5	12
78	Critical role of laser microdissection for genetic, epigenetic and proteomic analyses in pancreatic cancer. Expert Review of Molecular Diagnostics, 2011, 11, 695-701.	1.5	23
79	Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics, 2011, 12, 1641-1652.	0.6	45
80	Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town. Journal of Nephrology, 2011, 24, 381-385.	0.9	11
81	Ukrain Affects Pancreas Cancer Cell Phenotype in vitro by Targeting MMP-9 and Intra-/Extracellular SPARC Expression. Pancreatology, 2010, 10, 545-552.	0.5	19
82	Multidetector CT in the evaluation of retroperitoneal fat tissue infiltration in ductal adenocarcinoma of the pancreatic head: correlation with histopathological findings. Abdominal Imaging, 2010, 35, 465-470.	2.0	6
83	Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas. PLoS ONE, 2010, 5, e12653.	1.1	16
84	MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity. Cancer Research, 2010, 70, 4528-4538.	0.4	409
85	Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer. PLoS ONE, 2010, 5, e10630.	1.1	261
86	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	0.8	402
87	Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Laboratory Investigation, 2008, 88, 773-784.	1.7	34
88	Evaluation of vascular infiltration in resected patients for pancreatic cancer: comparison among multidetector CT, intraoperative findings and histopathology. Abdominal Imaging, 2007, 32, 737-742.	2.0	9
89	Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. Cancer Research, 2006, 66, 3928-3935.	0.4	307